在患有神经瘤下大脑关节出血的患者中使用他类药物治疗的效果:网络元分析
Xing Wang1, Qi Gan1, Chao You2,3
1Department of Neurosurgery, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan, People's Republic of China.
Neurocritical care
|April 2, 2024
概括
80毫克的simvastatin和40毫克的pravastatin显著降低了动脉瘤下arachnoid出血 (aSAH) 患者的延迟大脑缺血 (DCI) 风险. 短期的他类药物治疗也显示出预防DCI的好处.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 关于他类药物在治疗动脉瘤下关节出血 (aSAH) 的比较有效性,存在知识差距.
- 了解不同他类药物的相对疗效对于优化aSAH后患者的治疗结果至关重要.
研究的目的:
- 进行网络分析,比较不同类型的他类药物在aSAH患者中的疗效.
- 根据其在预防关键不良事件方面的有效性来对他类药物进行排名.
主要方法:
- 搜索了主要数据库 (MEDLINE,Embase,Pubmed,Cochrane) 的相关试验,直到2022年12月.
- 包括延迟脑缺血 (DCI),功能恢复和死亡率等结果.
- 用人网络元分析和积累性排名曲线下的面积 (SUCRA) 来确定治疗层次.
主要成果:
- 分析了13项涉及1885名患者的试验.
- 在预防DCI方面,阿托瓦斯塔丁20 mg,普拉瓦斯塔丁40 mg和西姆瓦斯塔丁80 mg在预防DCI方面表现出优于安慰剂的优势.
- 与simvastatin 40 mg相比,simvastatin 80 mg和pravastatin 40 mg显示了DCI风险的降低.
- 短期的他类药物治疗与DCI风险降低有关.
结论:
- 80毫克的simvastatin似乎是减少aSAH患者DCI的最有效的他类药物.
- 短期的他类药物治疗可能为DCI预防提供更大的好处.
- 建议进行进一步的随访研究以证实这些发现,特别是在高风险的aSAH患者中.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
659
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
659
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500